Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: In the time since the original proposal to move healthwriting companies from the blue blank to the orange blank, there have been several incremental updates to the blue blank by the NAIC Blanks Working Group to integrate portions of the orange blank into the blue blank. Meanwhile, the NAIC RBC Working Group has issued their proposal to change the health test for comment and appear to be moving forward with the proposal to revise the health test. This would obligate companies that write predominantly health business onto the orange blank rather than the blue blank, which they have historically used for reporting. Discover background of the revised health test, the incremental updates to the blue blank that have been implemented recently, additional incremental updates proposed for upcoming blue blanks, and the current status of the Health RBC Working Group proposal to revise the health test. Hear observations about companies that have opted to 'take the plunge' and move to the orange blank ahead of the revised health test as well as companies that have opted to remain on the blue blank and incrementally update as new requirements are integrated into the Blue blank. By attending the session, you will be able to: • Understand the context of the initiative to revise the NAIC health test. • Summarize the recent changes to the blue blank implemented by the Blanks Working Group that integrate portions of the orange blank into the blue blank. • Summarize the upcoming proposed changes to the blue blank by the Blanks Working Group that integrate additional portions of the orange blank into the blue blank. • Summarize the current status of the Health RBC Working Group proposal to revise the health test. • Provide industry perspective on companies that have opted to move to the orange blank ahead of the revised health test and companies that have opted to remain on the blue blank until the NAIC requires it.

Description: Digests of following discussions: 1. Mutual life insurance companies - their objectives and operating philosophy 2. State, provincial, and municipal employee pension plans - financing and other problems 3. Mortality and underwriting of individual policies for large amounts 4. Investing during the 1970's 5. Long-range viability and regulation of corporate pension plans 6. Forecasting the environment for business 7. Liabilities and surplus in the 1970's 8. Changing modes of family life - work and income over the life cycle 9. The role of the actuary in collective bargaining 10. Health insurance in the United States 11. Adjusted earnings

Description: 2021 ImpACT Conference - Session 12C: The Evolving Role of Actuaries in a Principles-Based World 10.29.21 Recording

Description: The ASU 2018-12 guidance, otherwise known as long-duration targeted improvements (LDTI), establishes a significant new category of benefit features called market risk benefits (MRB) that protect the contractholder from other-than-nominal capital market risk and expose the insurer to that risk. Insurers will have to measure market risk benefits at fair value. There are a few examples of MRB, Including the most common one— MGxBs on variable and indexed annuities. This change may bring significant volatility to earnings of these GMxB policies that are currently valued under the insurance accrual model (such as SOP 03-1). How to analyze the changes in volatility in MRBs became the natual question for many companies that haven't been valuing them on fair value basis. Besides the GMxBs, have you wondered when or if the guaranteed annuitization options offered by your company have other-than-norminal risk? By attending the session, you will: · Understand different types of MRBs. · Learn about ways to analyze the changes in volatility in MRBs from SOP 03-1. · Understand the accounting of MRB change for a contract under reinsurance going through spread and liability assumption updates. · Understand when the guaranteed annuitization options become MRB and how to evaluate that.

Description: 2021 ImpACT Conference - Session 6C: Reshaping the Roles of Actuaries - A Case Study 10.27.21 Recording

Description: The Life Meeting, is the result of combining the Life & Annuity Symposium (LAS) and the Valuation Actuarial Symposium (ValAct). The Life Meeting will offer sessions specific to pricing and valuation as well as sessions on emerging issues relevant to both groups. These common themes include InsurTech, diversity, accounting change and the current economic environment.

Description: After the arduous journeys IFRS 17 filers underwent to implement the standard, it would only make sense for insurers to seek the best return on their investment post effective date of 1/1/2023. Many insurers are now embarking a new phase of the journey that involves wrapping up any unfinished business as they might have taken a minimum compliance route to finish implementation and thinking about the knock-on effects the new standard has on the way they carry out business and perform financial reporting.

Description: This year’s Life Meeting was unable to take place in person as planned in New York City. We are looking forward to the Life Meeting returning to New York City in 2024!